About this test
Detects FLT3 internal tandem duplications and tyrosine kinase domain variants, which affect prognosis and eligibility for FLT3 inhibitors in AML.
- Clinical area
- Haematological malignancies
- Method
- PCR
- Sample
- EDTA whole blood · Bone marrow
- Report languages
- EN · AR · RU
When to order
At diagnosis of AML and at relapse.
Results are reported to the ordering physician and should be interpreted in clinical context.
Request this test
Offer this test to your patients.
Contract pricing and turnaround times are provided on request for laboratories and clinics.
Haematological malignancies
Other tests in this area
- JAK2 V617FMyeloproliferative neoplasms→
- JAK2 exon 12Polycythaemia vera→
- CALR exon 9Essential thrombocythaemia, myelofibrosis→
- MPL W515Essential thrombocythaemia, myelofibrosis→
- BCR::ABL1Chronic myeloid leukaemia, ALL→
- NPM1Acute myeloid leukaemia→
- IDH1 / IDH2AML, glioma→
- KIT D816VSystemic mastocytosis→
- Leukaemia fusion panelAcute leukaemia classification→